News | Contrast Media | February 04, 2016

Imaging probes can be sprayed on cancerous tissue rather than delivered via IV, speeding FDA approval time and immediately alerting surgeons if all cancer cells have been removed

February 4, 2016 — Akrotome Imaging Inc. received a major award from the National Institutes of Health (NIH) in November to complete development and commercialization of its new imaging platform.

The $1.7M grant will fund the development of an imaging instrument and a fluorescent molecular probe that “lights up” many kinds of previously invisible cancer cells, making it easier for surgeons to determine if all cancer cells have been removed or if additional surgeries are required.

Instead of requiring patients to receive large doses of probe via IV hours before the procedure, Akrotome developed something that could be easily sprayed on the tumor area to reveal traces of remaining cancer cells. Results are available in minutes and the patient does not need to be injected with probe.

While the probes can also be administered via IV, the external and topical applications of the probes mean they have fewer U.S. Food and Drug Administration (FDA) regulatory hurdles than competing probes and can reach the market faster and at a much lower cost.

Akrotome has a portfolio of probes that target cathepsins, cancer-associated enzymes that are expressed by 85 percent of solid tumors. Trials conducted by the company indicate the probe can highlight cancer cells with better than 95 percent accuracy. The probes and technologies were developed in the laboratories of Matthew Bogyo, Ph.D., at Stanford University and James Basilion, Ph.D., at Case Western Reserve University, with imaging capabilities provided by Indec Systems Inc.

Akrotome is currently moving its probes forward for use in skin and breast cancers. Future targets include colon, ovarian and lung tumors.

Research is supported by the National Cancer Institute of the National Institutes of Health under Award Number 2R44CA180296-02.

Related Content

News | Contrast Media

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
News | Contrast Media

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
News | Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
Feature | Contrast Media

The global contrast media market is projected to reach $5.9 billion by 2026 from $4.9 billion in 2021, at a CAGR of 3.7% ...

Time May 03, 2022
arrow
Sponsored Content | Case Study | Contrast Media Injectors

Product Indications and Use: CLARISCAN (gadoterate meglumine) is a gadolinium-based contrast agent indicated for ...

Time May 03, 2022
arrow
News | Contrast Media

April 6, 2022 — Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products ...

Time April 06, 2022
arrow
Sponsored Content | Videos | Contrast Media

With the use of contrast agents and radiotracers on the rise, GE Healthcare has seen increases in demand across their ...

Time February 23, 2022
arrow
Feature | Contrast Media Injectors | By Melinda Taschetta-Millane

Contrast media injectors are used to inject contrast agents to enhance the blood and perfusion in tissues. There have ...

Time January 19, 2022
arrow
News | Contrast Media

December 30, 2021 — The "Global Contrast Media Market Size, Share & Trends Analysis Report by Product Type (Iodinated ...

Time December 30, 2021
arrow
News | Contrast Media Injectors

December 13, 2021 — Qaelum NV announced that they enter into a strategic partnership with ulrich GmbH & Co. KG in Ulm to ...

Time December 13, 2021
arrow
Subscribe Now